In this article, we will discuss: 8 Best Genomics Stocks to Buy According to Analysts.
On June 8, 2026, Google DeepMind, Google.org, and the Wellcome Sanger Institute announced a five-year artificial intelligence collaboration for genomics. The partners said they will generate large-scale, artificial intelligence-friendly genomic datasets to address data gaps and train next-generation biological models to make biology more predictive. Dr. Julia Wilson, Chief Innovation and Impact Officer at the Sanger Institute, said the initiative combines “world-leading datasets” with AI expertise that will speed up biological data generation for shared scientific use.
As per the statement, the team will develop a framework for training AI models in genomics and encourage new collaborators to promote participation. Dr. Pushmeet Kohli, Vice President of AI for Science at Google DeepMind, stated that the project will create “the data backbone needed to decode the complexities of biological processes.” Anna Koivuniemi, Head of the Google DeepMind Impact Accelerator, stated that cross-sector collaboration is required to strengthen AI in genomics. Meanwhile, Leslie Yeh, Director of Google.org Scientific Progress, stated that open-access datasets will allow life-saving scientific advances in global research.
With that said, here are the 8 Best Genomics Stocks to Buy According to Analysts.
Methodology:
To list the 8 Best Genomics Stocks to Buy According to Analysts, we sifted through ETFs and several online rankings and shortlisted the stocks. Next, we chose the ones in which analysts see upside and which are popular among hedge funds as of Q1 2026. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment.
Note: All data was sourced on June 5.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
8. Natera, Inc. (NASDAQ:NTRA)
Analysts’ Upside Potential: 22.83%
On June 5, Goldman Sachs initiated coverage on Natera, Inc. (NASDAQ:NTRA) with a Neutral rating and a $245 price target, noting the firm’s leadership in the molecular residual disease testing market. Analyst Evie Koslosky pointed to “strong” commercial execution and a tumor-informed approach resulting in higher sensitivity. Goldman is expecting clearer operating leverage as the company continues reinvesting in growth.
On June 4, Natera, Inc. announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer. Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera assay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints.
CytoDyn CEO Jacob Lalezari said the partnership will generate insights into “ctDNA response kinetics and disease progression.” Natera’s Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners “better understand disease biology, treatment response, and patient outcomes.”
Natera, Inc. is a diagnostics company that discovers, develops, and markets genetic testing services. It provides Panorama non-invasive prenatal test, Vistara, horizon carrier screening, spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception, and non-invasive paternity testing.
7. Absci Corporation (NASDAQ:ABSI)
Analysts’ Upside Potential: 40.82%
On June 4, Leerink initiated coverage on Absci Corporation (NASDAQ:ABSI) with an Outperform rating and a $12 price target. The analyst stated that its “AI-native, clinical-stage story” is anchored by lead asset ABS-20 in Phase 1/2 for androgenetic alopecia, with Phase 2 in endometriosis expected to begin in Q4 2026. The firm flagged an “18-month catalyst path” with multiple readouts, calling it highly binary but among the most attractive in its coverage.
Separately, looking forward, Absci Corporation’s CEO Sean McClain said that 2026 will be a “data-rich year.” He also stated that ABS-201, a long-acting anti-PRLR antibody, could introduce a new mechanism in alopecia with infrequent dosing. The corporation said it completed dosing across four single ascending dose cohorts. It reported favorable safety and PK trends while starting multiple ascending dose cohorts.
The company announced ABS-202, a preclinical anti-PRLR program. It launched an endometriosis advisory board with experts from institutions including Yale, Duke, UCSF, and Mayo Clinic.
Absci Corporation is a drug and target discovery firm using deep learning AI and synthetic biology to expand the therapeutic potential of proteins.
6. Tempus AI, Inc. (NASDAQ:TEM)
Analysts’ Upside Potential: 42.00%
On June 3, Tempus AI, Inc. (NASDAQ:TEM) reported that it launched an open-source digital pathology consortium, alongside Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center, aiming to build a scalable platform and viewer. Chief of Pathology at YNHH, Chen Liu, said the group will “collaborate with leading academic and industry partners to help build an open, scalable, and interoperable digital pathology ecosystem” and commented that the shared standards will speed usage and improve workflows.
Days later, on June 11, Tempus AI, Inc. shifted focus to cardiology and reported that its AI-enabled ECG model, cleared in 2024, achieved successful multi-center validation across 4,017 patients, with results published in “Heart Rhythm.” The company said the model exceeded pre-specified performance thresholds in predicting one-year atrial fibrillation risk.
Brandon Fornwalt, Tempus SVP of cardiology, called the findings “an important step toward shifting cardiac care from late-stage intervention to early risk detection,” stating the tool consistently spotted risk across varied clinical environments.
Tempus AI, Inc. is a healthcare technology company that brings artificial intelligence and machine learning to healthcare. It builds platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology.
5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Analysts’ Upside Potential: 43.75%
On May 28, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) said partner GSK reported pivotal Phase 3 data for bepirovirsen. The corporation disclosed a 19% functional cure rate as compared to 0% on standard care, while reaching 26% in patients with lower viral activity. The trials, B-Well 1 and B-Well 2, met primary endpoints. Ionis stated that 233 of 1,220 treated patients achieved a functional cure versus none in the placebo group.
The company also reported 49% of treated patients reached surface antigen levels ≤100 IU/mL one year post-treatment, while 23% achieved sustained viral suppression at week 72.
Ionis mentioned adverse events included injection site reactions and temporary liver enzyme hikes.
Chief Executive Officer Brett P. Monia called the data “an important advance,” stating bepirovirsen could address chronic hepatitis B by reducing viral replication and suppressing surface antigen as well as stimulating an immune response.
Ionis Pharmaceuticals, Inc. is a firm that is involved in the development and marketing of human therapeutic drugs using antisense technology.
4. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Analysts’ Upside Potential: 63.79%
On May 26, Pacific Biosciences of California, Inc. (NASDAQ:PACB) began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform. The firm lowered the per-genome list price to $345 and authorized sub-$300 sequencing at scale. The company said the new chemistry cuts costs by about 30%. It also improved accuracy and yield through updates to its artificial intelligence-powered DeepConsensus algorithm developed with Google.
The company said beta testing across more than 1,400 runs showed higher yield and lower failure rates. Associate Professor and Senior Bioinformatician at Uppsala University, Adam Ameur, stated the system delivered “consistently strong run performance” with lower pricing and simplified workflows. CEO Christian Henry said AI advances, “improving data quality, speed, and usability,” are expanding what researchers can extract from each run.
Product Lead for Genomics at Google Research, Andrew Carroll, added that DeepConsensus upgrades introduce more data quality, while PacBio said expanded methylation detection and reusable consumables increase output and reduce costs.
Pacific Biosciences of California, Inc. is a firm that develops, manufactures, and markets advanced sequencing solutions for genetic analysis. It operates through America, Europe, the Middle East, and Africa, and Asia Pacific segments.
3. Cerus Corporation (NASDAQ:CERS)
Analysts’ Upside Potential: 66.05%
On June 8, Cerus Corporation (NASDAQ:CERS) closed a new debt facility with MidCap Financial, providing up to $110 million. The firm combined a five-year term loan with an asset-backed revolving loan. The company said the refinancing will cut annual cash interest expense by up to $3.5 million while reducing its outstanding term loan balance by about $30 million.
The company used initial proceeds and cash on hand to retire its existing $65 million term loan. It also pulled an initial $35 million tranche at closing and secured access to an extra $30 million in staged increments. A separate five-year revolving facility of up to $45 million adds capacity and flexibility.
Chief Financial Officer Kevin Green said the refinancing “strengthens our financial foundation,” and pointed out extended maturities and lower borrowing costs. The corporation highlighted deferred amortization for 48 months, followed by a 12-month repayment period.
Cerus Corporation is involved in the research, development, and manufacturing of biomedical and surgical products.
2. Beam Therapeutics Inc. (NASDAQ:BEAM)
Analysts’ Upside Potential: 75.45%
On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The firm detailed safety, durability, and reduced neutrophil elastase activity following treatment. It stated the data were made on topline results from 29 patients treated as of a February 10 cutoff, with extra insights from single-dose cohorts.
Chief Medical Officer Amy Simon said the findings support treating AATD “at the root cause of disease” using a one-time gene-editing therapy. Amy noted that Beam Therapeutics Inc. is advancing toward pivotal development. Separately, trial investigator John Hurst said the results suggest a single dose can restore AAT function, calling the approach “a paradigm shift.”
The company said it plans to pursue quick approval following FDA feedback, expecting to enroll about 50 more patients and start a pivotal cohort in the second half of 2026.
Beam Therapeutics Inc. is a biotechnology firm. It is involved in the establishment of an integrated platform for precision genetic medicines.
1. Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Analysts’ Upside Potential: 107.85%
On June 9, Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. (NASDAQ:NRIX)’ price target to $32 from $30. The firm maintained a “Buy” rating on the shares. The analyst called the company’s partnership with Roche “strategically sensible.” It also cited a 50:50 US profit-share structure for bexdeg as justifiable, given potential execution gains in chronic lymphocytic leukemia and development into I&I and neurology. Truist added that the deal validates bexdeg’s broader clinical potential while strengthening Nurix’s balance sheet.
On June 8, Reuters reported that Roche entered an exclusive licensing and partnership agreement with Nurix Therapeutics, Inc. worth up to $2.3 billion. The firm will receive $700 million upfront and milestone payments with development, regulatory, and sales targets. Roche said the deal centers on blood cancer drug bexobrutideg, with Phase III trials planned for the summer and potential launch around 2030. Deputy Chief Medical Officer Stefan Frings outlined the timeline, and Levi Garraway said the drug “could represent a major leap forward.”
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical business. It finds, develops, and commercializes innovative small molecules and antibody therapies based on cellular protein modification as a unique treatment method for cancer, inflammatory disorders, and other challenging diseases.
